LITTLE FALLS, N.J.,
March 10, 2016 /PRNewswire/
-- CANTEL MEDICAL CORP. (NYSE: CMN) reported record US
GAAP net income of $15,389,000, or
$0.37 per diluted share, on a 16.9%
increase in sales to a record $158,271,000 for the second quarter ended
January 31, 2016. This compares with
net income of $11,085,000 or
$0.27 per diluted share, on sales of
$135,430,000 for the second quarter
ended January 31, 2015. For the six
months ended January 31, 2016, the
Company reported record US GAAP net income of $29,643,000, or $0.71 per diluted share on a 14.6% increase in
sales to a record $312,050,000. This
compares with net income of $22,324,000, or $0.54 per diluted share, on sales of $272,241,000 for the six months ended
January 31, 2015.
Under non-GAAP financial measures, adjusted net income this
quarter increased 15.3% to $17,413,000, or $0.42 per diluted share, compared with adjusted
net income of $15,097,000, or
$0.36 per diluted share for the same
quarter last year. For the six months ended January 31, 2016, the Company reported a 17.9%
increase in adjusted net income to $34,533,000, or $0.83 per diluted share compared to adjusted net
income for the six months ended January 31,
2015 of $29,282,000, or
$0.70 per diluted share.
Andrew Krakauer, Cantel's Chief
Executive Officer stated, "We are pleased to have delivered record
sales and earnings performance this quarter. Our 16.9%
reported sales growth can be broken down into strong organic growth
of 12.1%, a 0.7% decline due to foreign currency translation, with
acquisitions making up the remaining 5.5% demonstrating the
continued success of our acquisition program. The majority of this
quarter's excellent performance was driven by the Endoscopy
business. All three of our major business units including Water
Purification and Filtration and Healthcare Disposables, in addition
to Endoscopy have greatly benefited from continued investments in
new product development, sales and marketing programs and the
integration of recent acquisitions. We are also pleased to report
gross margins improved approximately 100 basis points compared with
the same quarter last year."
Krakauer added, "Our Endoscopy segment led sales growth for the
company this quarter with a remarkable year-over-year increase of
38.1%, of which 26.5% was organic. This fast growing segment
represented over 50% of Cantel's total revenue this quarter. All
product categories in this segment were strong including procedure
room products, reprocessing equipment, disinfectants, as well as
service and spare parts. This was the first full quarter for
our newly acquired United
Kingdom-based Medical Innovations Group Holdings Limited
business. We are pleased that sales in this leading global provider
of endoscope storage and transport systems are doing well and
meeting our expectations.
Compared to the same quarter last year, sales in our Water
Purification and Filtration unit grew by 2.1%. Organic sales growth
of 0.9% in this segment was driven by increased shipments of
commercial and industrial water purification equipment. We saw a
good increase in orders and backlog during the quarter for our
dialysis water purification equipment products. In our Healthcare
Disposables segment, sales increased by 3.3% as compared to the
same quarter last year. Organic sales growth was flat. On a
positive note, we closed the acquisition of NAMSA's Sterility
Assurance Products Division on March
1. This acquisition reflects our continued focus on
sterility assurance as a key growth driver for our Healthcare
Disposable segment. Overall, revenue growth in all our operating
units drove improved operating earnings."
The Company further reported that its balance sheet at
January 31, 2016 included current
assets of $196,546,000, including
cash of $21,604,000, a current ratio
of 3:1, gross debt of $133,500,000
and stockholders' equity of $427,452,000. Krakauer stated, "The Company
has a strong balance sheet and continues to generate significant
cash flow and EBITDAS. Compared to the first six months of last
year, Cash Flow from Operations and Adjusted EBITDAS grew by 50%
and 19%, respectively to $28.3
million and $65.5 million,
respectively."
Cantel Medical is a leading global company dedicated to
delivering innovative infection prevention and control products and
services for patients, caregivers, and other healthcare providers
which improve outcomes, enhance safety and help save lives.
Our products include specialized medical device reprocessing
systems for endoscopy and renal dialysis, advanced water
purification equipment, sterilants, disinfectants and cleaners,
sterility assurance monitoring products for hospitals and dental
clinics, disposable infection control products primarily for dental
and GI endoscopy markets, dialysate concentrates, hollow fiber
membrane filtration and separation products. Additionally, we
provide technical service for our products.
The Company will hold a conference call to discuss the results
for the second quarter ended January 31,
2016 on Thursday, March 10,
2016 at 11:00 AM Eastern time.
To participate in the conference call, dial (877) 407-8033
approximately 5 to 10 minutes before the beginning of the call. If
you are unable to participate, a digital replay of the call will be
available from Thursday, March 10, 2016 at 2:00
PM through midnight on May 10,
2016 by dialing (877) 660-6853 and using conference ID #
13631451.
The call will be simultaneously broadcast live over the Internet
on vcall.com at
http://www.investorcalendar.com/IC/CEPage.asp?ID=174750. A
replay of the webcast will be available on PrecisionIR for 90 days
and via the investor relations page of the Cantel web site.
For further information, visit the Cantel website at
www.cantelmedical.com.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including, without limitation, the risks detailed in Cantel's
filings and reports with the Securities and Exchange Commission.
Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or
anticipated.
CANTEL MEDICAL
CORP.
|
CONDENSED
CONSOLIDATED STATEMENTS OF INCOME
|
(In thousands, except
per share data)
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
Six Months
Ended
|
|
|
January
31,
|
|
January
31,
|
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$ 158,271
|
|
$ 135,430
|
|
$ 312,050
|
|
$ 272,241
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
|
85,934
|
|
74,839
|
|
168,515
|
|
151,136
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
|
72,337
|
|
60,591
|
|
143,535
|
|
121,105
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
Selling
|
|
22,620
|
|
19,257
|
|
44,080
|
|
38,668
|
General and
administrative
|
|
22,252
|
|
19,822
|
|
44,449
|
|
38,329
|
Research and
development
|
|
3,069
|
|
3,211
|
|
6,834
|
|
6,760
|
Total operating
expenses
|
|
47,941
|
|
42,290
|
|
95,363
|
|
83,757
|
|
|
|
|
|
|
|
|
|
Income from
operations
|
|
24,396
|
|
18,301
|
|
48,172
|
|
37,348
|
|
|
|
|
|
|
|
|
|
Interest expense,
net
|
|
871
|
|
646
|
|
1,616
|
|
1,180
|
|
|
|
|
|
|
|
|
|
Income before income
taxes
|
|
23,525
|
|
17,655
|
|
46,556
|
|
36,168
|
|
|
|
|
|
|
|
|
|
Income
taxes
|
|
8,136
|
|
6,570
|
|
16,913
|
|
13,844
|
|
|
|
|
|
|
|
|
|
Net
income
|
|
$ 15,389
|
|
$ 11,085
|
|
$ 29,643
|
|
$ 22,324
|
|
|
|
|
|
|
|
|
|
Earnings per common
share - diluted
|
|
$ 0.37
|
|
$ 0.27
|
|
$ 0.71
|
|
$ 0.54
|
|
|
|
|
|
|
|
|
|
Dividends per common
share
|
|
$
-
|
|
$ 0.05
|
|
$ 0.06
|
|
$ 0.05
|
|
|
|
|
|
|
|
|
|
Weighted average
shares - diluted
|
|
41,748
|
|
41,584
|
|
41,708
|
|
41,569
|
|
|
|
|
|
|
|
|
|
CANTEL MEDICAL
CORP.
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(In
thousands)
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
January
31,
|
|
July 31,
|
|
|
2016
|
|
2015
|
Assets
|
|
|
|
|
Current assets
|
|
$ 196,546
|
|
$ 188,361
|
Property and equipment,
net
|
|
69,995
|
|
62,541
|
Intangible assets,
net
|
|
113,805
|
|
85,836
|
Goodwill
|
|
277,847
|
|
241,951
|
Other assets
|
|
5,135
|
|
5,342
|
|
|
$ 663,328
|
|
$ 584,031
|
|
|
|
|
|
Liabilities and stockholders' equity
|
|
|
|
Current
liabilities
|
|
$ 66,107
|
|
$ 70,624
|
Long-term debt
|
|
133,500
|
|
78,500
|
Other long-term
liabilities
|
|
36,269
|
|
28,274
|
Stockholders'
equity
|
|
427,452
|
|
406,633
|
|
|
$ 663,328
|
|
$ 584,031
|
|
|
|
|
|
SUPPLEMENTARY
INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL
MEASURES
|
|
In evaluating our
operating performance, we supplement the reporting of our financial
information determined under accounting principles generally
accepted in the United States ("GAAP") with certain internally
driven non-GAAP financial measures, namely (i) adjusted net income,
(ii) adjusted diluted earnings per share ("EPS"), (iii) income
before interest, taxes, depreciation, amortization and stock-based
compensation expense ("EBITDAS"), (iv) EBITDAS adjusted for
atypical items ("Adjusted EBITDAS") and (v) net debt. These
non-GAAP financial measures are indicators of the Company's
performance that is not required by, or presented in accordance
with, GAAP. They are presented with the intent of providing greater
transparency to financial information used by us in our financial
analysis and operational decision-making. We believe that these
non-GAAP measures provide meaningful information to assist
investors, shareholders and other readers of our Condensed
Consolidated Financial Statements in making comparisons to our
historical operating results and analyzing the underlying
performance of our results of operations. These non-GAAP financial
measures are not intended to be, and should not be, considered
separately from, or as an alternative to, the most directly
comparable GAAP financial measures.
|
|
|
Reconciliations of
Net Income and Diluted EPS to Adjusted Net Income and Adjusted
Diluted EPS
|
|
We define adjusted
net income and adjusted diluted EPS as net income and diluted EPS,
respectively, adjusted to exclude amortization, acquisition related
items, significant reorganization and restructuring charges, major
tax events and other significant items management deems atypical or
non-operating in nature.
|
|
For the three and six
months ended January 31, 2016 and 2015, we made adjustments to net
income and diluted EPS to exclude (i) amortization expense, (ii)
acquisition related items impacting current operating performance
including transaction and integration charges and ongoing fair
value adjustments and (iii) with respect to the current year
periods, the impact of favorable tax legislation to arrive at our
non-GAAP financial measures, adjusted net income and adjusted
EPS.
|
|
Amortization expense
is a non-cash expense related to intangibles that were primarily
the result of business acquisitions. Our history of acquiring
businesses has resulted in significant increases in amortization of
intangible assets that reduced the Company's net income. The
removal of amortization from our overall operating performance
helps in assessing our cash generated from operations including our
return on invested capital, which we believe is an important
analysis for measuring our ability to generate cash and invest in
our continued growth.
|
|
Acquisition related
items consist of (i) fair value adjustments to contingent
consideration and other contingent liabilities resulting from
acquisitions, (ii) due diligence, integration, legal fees and other
transaction costs associated with specific acquisitions, and (iii)
acquisition accounting charges for the amortization of the initial
fair value adjustments of acquired inventory and deferred revenue.
The adjustments of contingent consideration and other contingent
liabilities are periodic adjustments to record such amounts at fair
value at each balance sheet date. Given the subjective nature of
the assumptions used in the determination of fair value
calculations, fair value adjustments may potentially cause
significant earnings volatility that are not representative of our
operating results. Similarly, due diligence, integration, legal and
other acquisition costs associated with specific acquisitions,
including acquisition accounting charges relating to recording
acquired inventory and deferred revenue at fair market value, can
be significant and also adversely impact our effective tax rate as
certain costs are often not tax-deductible. Since all of these
acquisition related items are atypical and often mask underlying
operating performance, we excluded these amounts for purposes of
calculating these non-GAAP financial measures to facilitate an
evaluation of our current operating performance and a comparison to
past operating performance.
|
|
Tax legislation was
enacted in the United States and internationally that enabled us to
record favorable tax benefits in our second quarter of fiscal 2016
relating to the entire calendar 2015. Since these favorable tax
benefits are largely unrelated to our second quarter's income
before taxes and is unrepresentative of our normal effective tax
rate, we excluded its impact on net income and EPS for purposes of
calculating these non-GAAP financial measures to facilitate an
evaluation of our current performance and a comparison to past
performance.
|
|
The reconciliations
of net income to adjusted net income were calculated as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
Months Ended
|
|
Six
Months Ended
|
(Amounts in
thousands)
|
|
January
31,
|
|
January
31,
|
(Unaudited)
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
Net Income, as
reported
|
|
$
15,389
|
|
$
11,085
|
|
$ 29,643
|
|
$ 22,324
|
Intangible
amortization (1)
|
|
3,297
|
|
3,232
|
|
6,391
|
|
6,188
|
Acquisition related
items (2)
|
|
597
|
|
2,256
|
|
1,531
|
|
3,512
|
Income tax benefit on
above adjustments
|
|
(1,070)
|
|
(1,476)
|
|
(2,232)
|
|
(2,742)
|
Tax legislative
changes (3)
|
|
(800)
|
|
-
|
|
(800)
|
|
-
|
Adjusted net
income
|
|
$
17,413
|
|
$
15,097
|
|
$ 34,533
|
|
$ 29,282
|
|
|
|
|
|
|
|
|
|
|
(1) Amounts are
recorded in general and administrative expenses.
|
(2) For the three and
six months ended January 31, 2016, acquisition related items of
$311,000 and $571,000, respectively, were recorded in cost of sales
and $286,000 and $960,000, respectively, were recorded in general
administrative expenses. For the three and six months ended January
31, 2015, acquisition related items of $876,000 and $1,543,000,
respectively, were recorded in cost of sales and $1,380,000 and
$1,969,000, respectively, were recorded in general administrative
expenses.
|
(3) Amounts are
recorded in income taxes.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The reconciliations
of diluted EPS to adjusted diluted EPS were calculated as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
Months Ended
|
|
Six Months
Ended
|
|
|
January
31,
|
|
January
31,
|
(Unaudited)
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
Diluted EPS, as
reported
|
|
$
0.37
|
|
$
0.27
|
|
$ 0.71
|
|
$ 0.54
|
Intangible
amortization, net of tax
|
|
0.06
|
|
0.05
|
|
0.11
|
|
0.10
|
Acquisition related
items, net of tax
|
|
0.01
|
|
0.04
|
|
0.03
|
|
0.07
|
Tax legislative
changes
|
|
(0.02)
|
|
-
|
|
(0.02)
|
|
-
|
Adjusted diluted EPS
(1)
|
|
$
0.42
|
|
$
0.36
|
|
$ 0.83
|
|
$ 0.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) The summation of
diluted EPS for the six months ended January 31, 2015 does not
equal the adjusted diluted EPS of $0.70 due to rounding.
|
Reconciliation of
EBITDAS and Adjusted EBITDAS with Net Income
|
|
We believe EBITDAS is
an important valuation measurement for management and investors
given the increasing effect that non-cash charges, such as
stock-based compensation, amortization related to acquisitions and
depreciation of capital equipment, has on the Company's net income.
In particular, acquisitions have historically resulted in
significant increases in amortization of intangible assets that
reduce the Company's net income. Additionally, we regard EBITDAS as
a useful measure of operating performance and cash flow before the
effect of interest expense and is a complement to operating income,
net income and other GAAP financial performance
measures.
|
|
We define Adjusted
EBITDAS as EBITDAS excluding the same atypical items as previously
described as adjustments to net income. We use Adjusted EBITDAS
when evaluating the operating performance of the Company because we
believe the exclusion of such atypical items, of which a
significant portion are non-cash items, is necessary to provide the
most accurate measure of on-going core operating results and to
evaluate comparative results period over period.
|
|
|
|
|
|
|
|
|
|
The reconciliations
of EBITDAS and Adjusted EBITDAS with net income were calculated as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
Six Months
Ended
|
(Amounts in
thousands)
|
|
January
31,
|
|
January
31,
|
(Unaudited)
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
|
|
|
|
|
Net income, as
reported
|
|
$ 15,389
|
|
$ 11,085
|
|
$ 29,643
|
|
$ 22,324
|
|
|
|
|
|
|
|
|
|
Interest expense,
net
|
|
871
|
|
646
|
|
1,616
|
|
1,180
|
Income
taxes
|
|
8,136
|
|
6,570
|
|
16,913
|
|
13,844
|
Depreciation
|
|
2,871
|
|
2,541
|
|
5,693
|
|
4,853
|
Amortization
|
|
3,297
|
|
3,232
|
|
6,391
|
|
6,188
|
Loss on disposal of
fixed assets
|
|
11
|
|
24
|
|
111
|
|
37
|
Stock-based
compensation expense
|
|
1,875
|
|
1,420
|
|
3,595
|
|
3,001
|
|
|
|
|
|
|
|
|
|
EBITDAS
|
|
32,450
|
|
25,518
|
|
63,962
|
|
51,427
|
|
|
|
|
|
|
|
|
|
Acquisition related
items
|
|
597
|
|
2,256
|
|
1,531
|
|
3,512
|
|
|
|
|
|
|
|
|
|
Adjusted
EBITDAS
|
|
$ 33,047
|
|
$ 27,774
|
|
$ 65,493
|
|
$ 54,939
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
Debt with Net Debt
|
|
We define net debt as
long-term debt less cash and cash equivalents. Each of the
components of net debt appears in the Condensed Consolidated
Balance Sheets. We believe that the presentation of net debt
provides useful information to investors because we review net debt
as part of our management of our overall liquidity, financial
flexibility, capital structure and leverage.
|
|
|
|
|
|
|
|
|
|
The reconciliations
of debt with net debt were calculated as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Amounts in
thousands)
|
|
January
31,
|
|
July 31,
|
|
|
|
|
(Unaudited)
|
|
2016
|
|
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term
debt
|
|
$ 133,500
|
|
$ 78,500
|
|
|
|
|
Less cash and cash
equivalents
|
|
(21,604)
|
|
(31,720)
|
|
|
|
|
Net debt
|
|
$ 111,896
|
|
$ 46,780
|
|
|
|
|
|
|
|
|
|
|
|
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cantel-medical-reports-record-results-for-the-second-quarter-ended-january-31-2016-300233824.html
SOURCE Cantel Medical